Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Basic Medicine
  4. Vol 1, Issue 1, 2023

Progress in the application of intestinal flora in the treatment of diabetes

Download as PDF

DOI: 10.23977/medbm.2023.010104 | Downloads: 7 | Views: 468

Author(s)

Ruohan Wen 1, Xingshuo Huang 1, Houru Liu 1, Dehong Yu 1

Affiliation(s)

1 North China University of Science and Technology, Tangshan, 063210, Hebei, China

Corresponding Author

Dehong Yu

ABSTRACT

Intestinal flora is closely related to human health, and its imbalance is related to the occurrence and development of many diseases, such as intestinal inflammation, intestinal tumors, obesity, diabetes, autoimmune diseases, etc. It has a great effect on host nutrition, exogenous and drug metabolism, and the interaction between intestinal flora and host ensures the health of body function, and also affects the participation in various physiological activities and functions of the body.

KEYWORDS

Diabetes, intestinal flora, metabolism, traditional Chinese medicine

CITE THIS PAPER

Ruohan Wen, Xingshuo Huang, Houru Liu, Dehong Yu, Progress in the application of intestinal flora in the treatment of diabetes. MEDS Basic Medicine (2023) Vol. 1: 18-22. DOI: http://dx.doi.org/10.23977/medbm.2023.010104.

REFERENCES

[1] Gurung M, Li Z, You H, et al. Role of gut microbiota in type 2 diabetes pathophysiology[J]. EBioMedicine, 2020, 51: 102590-102599.
[2] Zhang Y, Peng Y, Zhao L, et al. Regulating the gut microbiota and SCFAs in the faeces of T2DM rats should be one of antidiabetic mechanisms of mogrosides in the fruits of Siraitia grosvenorii[J]. J Ethnopharmacol, 2021, 274: 114033-114044.
[3] Gu Y, Wang X, Li J, et al. Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment[J]. Nat Commun, 2017, 8(1): 1785-1797.
[4] Bi R , Gao J , Pan L ,et al.Progress in the Treatment of Diabetes Mellitus Based on Intestinal Flora Homeostasis and the Advancement of Holistic Analysis Methods:[J].Natural Product Communications, 2020, 15(4):109138-103.DOI:10.1177/1934578X20918418.
[5] Eckburg P B, Bik E M, Bernstein C N, et al. Diversity of the human intestinal microbial flora[J]. Science, 2005, 308(5728): 1635-1638.
[6] Sheng Y, Zheng S, Ma T, et al. Mulberry leaf alleviates streptozotocin-induced diabetic rats by attenuating NEFA signaling and modulating intestinal microflora[J]. Sci Rep, 2017, 7(1): 12041-12052.
[7] Xu T, Ge Y, Du H, et al. Berberis kansuensis extract alleviates type 2 diabetes in rats by regulating gut microbiota composition[J]. J Ethnopharmacol, 2021, 273: 113995-114004.
[8] Zhao X Q, Guo S, Lu Y Y, et al. Lycium barbarum L. leaves ameliorate type 2 diabetes in rats by modulating metabolic profiles and gut microbiota composition[J]. Biomed Pharmacother, 2020, 121: 109559-109572.
[9] Meng X, Ma J, Kang S Y, et al. Jowiseungki decoction affects diabetic nephropathy in mice through renal injury inhibition as evidenced by network pharmacology and gut microbiota analyses[J]. Chin Med, 2020, 15: 24-43.
[10] Li M, Ding L, Hu Y L, et al. Herbal formula LLKL ameliorates hyperglycaemia, modulates the gut microbiota and regulates the gut-liver axis in Zucker diabetic fatty rats[J]. J Cell Mol Med, 2021, 25(1): 367-382.
[11] Gao K, Yang R, Zhang J, et al. Effects of Qijian mixture on type 2 diabetes assessed by metabonomics, gut microbiota and network pharmacology[J]. Pharmacol Res, 2018, 130: 93-109.
[12] Xiong Y, Li Q, Chen X, et al. Identification of the active compound of Liu Wei Di Huang Wan for treatment of gestational diabetes mellitus via network pharmacology and molecular docking[J]. J Diabetes Res, 2022, 2022: 4808303-4808321.
[13] Yi Z Y, Chen L, Wang Y, et al. The potential mechanism of Liu-Wei-Di-Huang pills in treatment of type 2 diabetic mellitus: from gut microbiota to short-chain fatty acids metabolism[J]. Acta Diabetol, 2022, 59(10): 1295-1308.
[14] Hu N, Zhang Q, Wang H, et al. Comparative evaluation of the effect of metformin and insulin on gut microbiota and metabolome profiles of type 2 diabetic rats induced by the combination of streptozotocin and high-fat diet[J]. Front Pharmacol, 2021, 12: 794103-794121.
[15] Molina-Vega M, Picon-Cesar M J, Gutierrez-Repiso C, et al. Metformin action over gut microbiota is related to weight and glycemic control in gestational diabetes mellitus: A randomized trial[J]. Biomed Pharmacother, 2022, 145: 112465-112474.
[16] Su B, Liu H, Li J, et al. Acarbose treatment affects the serum levels of inflammatory cytokines and the gut content of bifidobacteria in Chinese patients with type 2 diabetes mellitus[J]. J Diabetes, 2015, 7(5): 729-739.
[17] Liao X, Song L, Zeng B, et al. Alteration of gut microbiota induced by DPP-4i treatment improves glucose homeostasis [J]. EBioMedicine, 2019, 44: 665-674.
[18] Herat L Y, Ward N C, Magno A L, et al. Sodium glucose co-transporter 2 inhibition reduces succinate levels in diabetic mice[J]. World J Gastroenterol, 2020, 26(23): 3225-3235.
[19] Oh T J, Sul W J, Oh H N, et al. Butyrate attenuated fat gain through gut microbiota modulation in db/db mice following dapagliflozin treatment[J]. Sci Rep, 2019, 9(1): 20300-20311.
[20] Zhang M, Feng R, Yang M, et al. Effects of metformin, acarbose, and sitagliptin monotherapy on gut microbiota in Zucker diabetic fatty rats[J]. BMJ Open Diabetes Res Care, 2019, 7(1): e000717-e000728.
[21] Nie Q, Chen H, Hu J, et al. Dietary compounds and traditional chinese medicine ameliorate type 2 diabetes by modulating gut microbiota[J]. Crit Rev Food Sci Nutr, 2019, 59(6): 848-863.
[22] Diaz-Rizzolo D A, Kostov B, Lopez-Siles M, et al. Healthy dietary pattern and their corresponding gut microbiota profile are linked to a lower risk of type 2 diabetes, independent of the presence of obesity[J]. Clin Nutr, 2020, 39(2): 524-532.
[23] Sofi M H, Gudi R, Karumuthil-Melethil S, et al. pH of drinking water influences the composition of gut microbiome and type 1 diabetes incidence[J]. Diabetes, 2014, 63(2): 632-644.
[24] Pasini E, Corsetti G, Assanelli D, et al. Effects of chronic exercise on gut microbiota and intestinal barrier in human with type 2 diabetes[J]. Minerva Med, 2019, 110(1): 3-11.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 453
Visits: 14591

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.